Provider review
WellMedr Review: It Mixes a GLP-1 With NAD+ and Sells It for Focus
WellMedr sells the usual compounded GLP-1s, and then it sells something this site has not seen anywhere else: a GLP-1 mixed into the same injection as NAD+ and vitamin B12, marketed for the brain. "Energy & Focus+" is compounded tirzepatide "formulated with NAD+ and Vitamin B12… Designed for individuals seeking enhanced cognitive and physical output". A second version does it with semaglutide. A third, "Muscle & Energy+", is an oral microdose tirzepatide with NAD+, L-carnitine and B12, sold explicitly "without a primary weight-loss emphasis". Every ingredient in those products is real; no registered trial has tested any of the combinations, and injected NAD+ has no completed human trial by itself. Its core compounded line, meanwhile, never names the molecule in the product title — you have to read the URL, where "Compounded GLP-1/GIP" turns out to be `injectable-tirzepatide`.
Approved + compounded
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.wellmedr.com. A link is not a recommendation to take anything.
Provenance
What WellMedr actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Ozempic® (brand, cash-pay) — $1,399 a month for Ozempic and $1,599 for Zepbound, month-to-month — several times the manufacturers' published direct self-pay prices for the same products.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Energy & Focus+ (compounded tirzepatide with NAD+ and B12) — No standing price is rendered on the product page — the Shopify variant returns $0.00 and the figure appears after the eligibility quiz. WellMedr's weight-loss page advertises its tirzepatide line "Starting At $99 a month", "Shipped every 4 weeks".
- Energy & Focus+ (compounded semaglutide with NAD+ and B12) — Not rendered on the product page; the figure appears after the eligibility quiz.
- Muscle & Energy+ (oral microdose GLP-1/GIP) — Not rendered on the product page; the figure appears after the eligibility quiz.
- Compounded GLP-1/GIP (handle: injectable-tirzepatide) — "Monthly Plan Starting At $99 a month… Tirzepatide shipped every 4 weeks." ⚠ Four-week shipping means about 13 charges a year rather than 12, so a "$99 a month" plan is roughly $1,287 a year, not $1,188.
- Compounded GLP-1 (handle: injectable-semaglutide) — Priced within the same plan structure, shipped every four weeks; the figure appears after the eligibility quiz.
Evidence
Is there a human trial at all?
One row per product, graded on how far the published human evidence goes for the use it is sold for — not for the molecule in general. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Products with a human trial
Out of 6 reviewed here.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from WellMedr’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Energy & Focus+ (compounded tirzepatide with NAD+ and B12)Tirzepatide with NAD+ and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded Tirzepatide injection formulated with NAD+ and Vitamin B12 to help support balanced focus, sustained energy, and metabolic performance. Designed for individuals seeking enhanced cognitive and physical output through GLP-1/GIP–based therapy.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no registered trial of tirzepatide co-formulated or co-administered with NAD+, in any phase, for any endpoint. Each part fails separately as well: injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim and no registered study reporting a COGNITIVE endpoint by any route, and the tirzepatide programme (SURMOUNT) measured weight and cardiometabolic outcomes, never cognition or focus. The searches discriminate — run in the same pass, tirzepatide alone returns 158 registry records naming it as an intervention.
This is a combination product sold for an indication neither of its active components has been tested for. Tirzepatide has a large phase 3 programme, and every trial in it measured weight, glycaemia or cardiovascular outcomes — not focus, not cognition, not "cognitive output". Injected NAD+ has no completed randomised human trial at all, and no registered study of it reports a cognitive endpoint by any route. And no trial has tested the two together, in one syringe or otherwise. So "designed for individuals seeking enhanced cognitive and physical output" describes an intention rather than a demonstrated effect, and the word "formulated" carries an implication of deliberate pharmacological design that nothing published supports. ⚠ B12 is the one component with a real cognitive story, and it is a narrow one: correcting a B12 DEFICIENCY can improve cognition. That is not a reason to give B12 to someone who is not deficient, and the page does not raise the distinction.1,2
Energy & Focus+ (compounded semaglutide with NAD+ and B12)Semaglutide with NAD+ and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded Semaglutide injection formulated with NAD+ and Vitamin B12 to help support balanced energy, focus, and metabolic performance. Designed for individuals seeking sustained mental and physical vitality alongside GLP-1 benefits.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no registered trial of semaglutide co-formulated or co-administered with NAD+, in any phase, for any endpoint. Separately, injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim and none reporting a cognitive endpoint, and the semaglutide programme — STEP for weight, SUSTAIN for glycaemia, SELECT for cardiovascular outcomes — reported none of "energy", "focus" or "mental vitality" as an endpoint.
The same combination logic with the other molecule, and the same gap. "Sustained mental and physical vitality alongside GLP-1 benefits" pairs an unevidenced claim with an evidenced one in a single phrase: the GLP-1 benefits are real and well documented for weight and glycaemia, and the mental vitality is not documented at all. Putting them in the same sentence lets the established half carry the unestablished one. No trial has tested semaglutide with NAD+, and no trial of either reports a cognitive or energy endpoint.1,3
Muscle & Energy+ (oral microdose GLP-1/GIP)Tirzepatide with NAD+, L-carnitine and vitamin B12 · Compounded (503A)No trial supports this claim
“Compounded oral microdose GLP-1/GIP* (contains Tirzepatide), formulated with NAD+, L-Carnitine, and Vitamin B12 to help support energy, focus, and metabolic performance—without a primary weight-loss emphasis.”
No human trial
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed trial of a sub-therapeutic "microdose" tirzepatide regimen against any endpoint, no registered trial of an ORAL compounded tirzepatide preparation, and no trial of tirzepatide combined with NAD+, L-carnitine or B12. Four separate things are unstudied here — the dose, the route, the combination and the indication — and no registered study of any of them exists.
This product stacks four unevidenced choices on one molecule. The DOSE is a deliberate microdose, and no completed trial has tested a sub-therapeutic tirzepatide regimen against any endpoint. The ROUTE is oral, and no registered trial has tested a compounded oral tirzepatide. The COMBINATION adds NAD+, L-carnitine and B12, none of which has been studied with tirzepatide. And the INDICATION is explicitly not weight loss — "without a primary weight-loss emphasis" — which is the only thing tirzepatide has ever been trialled for. To WellMedr's credit the description does name the molecule, unlike its core compounded line, and the asterisk on "GLP-1/GIP*" signals that a qualification exists.2
Compounded GLP-1/GIP (handle: injectable-tirzepatide)Tirzepatide · Compounded (503A)Claim matches the trials
“Clinically guided treatment designed to regulate appetite, enhance metabolism, and support lasting weight management—all through convenient online care. Includes: Licensed provider review and ongoing medical oversight. Medical Weight-Care Coach for guidance and progress support. Tailored dosage adjustments based on your individual response.”
Phase 3 trials
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide at the highest tolerated dose over 72 weeks, with lifestyle intervention in every arm.
Nothing here outruns the trials: appetite regulation and weight management are exactly what tirzepatide has been shown to do, no percentage is quoted and no trial is name-dropped. "Enhance metabolism" is the loosest phrase and is defensible as shorthand for the metabolic effects that were measured. ⚠ The problem with this product is not the claim but the label: the title says "Compounded GLP-1/GIP" and the description never names the molecule. A buyer only learns it is tirzepatide from the URL slug, `injectable-tirzepatide`. WellMedr names the molecule plainly for its branded products ("Contains Tirzepatide") and for its combination products, so the omission is specific to the core compounded line.2
Compounded GLP-1 (handle: injectable-semaglutide)Semaglutide · Compounded (503A)Claim matches the trials
“A once-weekly injectable treatment designed to help regulate appetite, balance blood sugar, and support long-term weight management—all through convenient online care.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks. No compounded semaglutide from any seller has been through a registered trial.
Appetite regulation, blood-sugar balance and weight management are all established for semaglutide, and WellMedr claims no magnitude and names no trial, so nothing here reaches past the evidence. The same labelling problem applies: "Compounded GLP-1" is the product name, the description never says semaglutide, and the molecule appears only in the URL slug `injectable-semaglutide`. The standing caveat is unstated — STEP 1 tested the approved finished product, not a compounded preparation.3
Ozempic® (brand, cash-pay)Semaglutide · FDA-approvedClaim matches the trials
“Ozempic starting at $1,399. Contains Semaglutide. Month-to-month plan. Includes: Licensed provider review and ongoing medical oversight. Medical Weight-Care Coach for personalized guidance and accountability. Tailored dosage adjustments based on your progress and response.”
Phase 3 trials
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The semaglutide weight-management programme. Ozempic's own approval is for type 2 diabetes; Wegovy is the weight approval of the same molecule.
For the branded products WellMedr does the thing it declines to do elsewhere: it names the molecule. "Contains Semaglutide" on Ozempic and "Contains Tirzepatide" on Zepbound are exactly the disclosures missing from its compounded line. Nothing is claimed beyond what the products are. ⚠ The price is the issue: $1,399 a month for Ozempic and $1,599 for Zepbound are far above what the manufacturers charge self-paying patients through their own direct channels, and any telehealth prescriber can route a prescription there instead. ⚠ Worth noting for accuracy: Ozempic is approved for type 2 diabetes, and Wegovy is the weight-management approval of the same molecule — so selling Ozempic on a weight-loss page describes an off-label use, which is lawful and common but is not the approved indication.3
Dispensing chain
Who actually fills your prescription
Read the full account
No dispensing pharmacy is named anywhere on the site. The assurances offered are two phrases, and neither describes anything checkable. "We work only with licensed U.S. providers and ACCREDITED PHARMACIES" names no accrediting body and no pharmacy. And the site-wide banner reads "FDA-REGULATED PHARMACIES", which is loose in the direction this whole category is loose: a 503A compounding pharmacy is licensed and inspected by its STATE board of pharmacy, not regulated by FDA; a 503B outsourcing facility does register with FDA, but registration is not regulation of the sort the phrase implies. WellMedr states no compounding category at all — neither 503A nor 503B appears on the site. ⚠ The corporate identity is published plainly: Wellmedr LLC, info@wellmedr.com and support@wellmedr.com, with a staffed telephone line on 1-888-397-6905, Monday to Saturday 8am–8pm ET. A published phone number with stated hours is more than several companies in this roster offer. ⚠ No individual clinician is named, and no medical group is identified. ⚠ One curiosity worth recording because it says something about how the site is maintained: the footer copyright reads "© wellmedr, 2025" on the product pages and "© 2026 WellMedr" on the weight-loss landing page.
Read on August 2026 from https://www.wellmedr.com/pages/get-started-weight-loss
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, lot number, potency result, sterility result, named laboratory or batch lookup is published for any product, and no pharmacy is named to ask. The site's only quality claim is the banner phrase "FDA-regulated pharmacies", which misdescribes how compounding pharmacies are overseen, and "accredited pharmacies" in the FAQ, which names no accrediting body. No compounding category is stated. ⚠ That gap matters more for this catalogue than for most, because WellMedr's distinctive products are COMBINATIONS — tirzepatide with NAD+ and B12 in one injection, and an oral microdose tirzepatide with NAD+, L-carnitine and B12. A multi-ingredient sterile preparation raises questions a single-molecule one does not: compatibility, stability and the potency of each component over time. Nothing on the site addresses any of them, and no document is offered. ⚠ No study, trial identifier or publication is cited anywhere on the site, for any product. ⚠ Its most prominent numerical claim is about the drug class rather than about WellMedr: "GLP-1 medications used by 1,000,000+ patients".
Read on August 2026 from https://www.wellmedr.com/pages/get-started-weight-loss
Licensing
Licensed to dispense, and where
Coverage
Not published — WellMedr declines to answer the question and defers it to the sign-up flow
Read the full licensing claim
WellMedr publishes no state list, and it is one of the few companies to be asked the question directly in its own FAQ and decline to answer it. "What states do you serve? We are expanding rapidly — eligibility is checked during sign-up." That is an answer about process rather than coverage: a prospective patient cannot find out whether they are eligible without starting an intake. `statesExcluded` is empty because naming exclusions would mean inventing them. Clinical oversight is described only as "licensed U.S. providers" and "U.S. licensed clinicians", with no medical group named, no individual clinician named and no licence number published. ⚠ The FAQ also carries a results-timeline claim on the same page: "How fast will I see results? Most members begin seeing results within the first few weeks." ⚠ WellMedr does publish a real contact route — 1-888-397-6905, Monday to Saturday, 8am to 8pm ET — plus separate privacy, terms, telehealth-consent and refund-and-cancellation documents, which is a fuller set of legal pages than several companies in this roster maintain.
Read on August 2026 from https://www.wellmedr.com/pages/get-started-weight-loss
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- It names the molecule plainly for its branded products — Ozempic "Contains Semaglutide", Zepbound "Contains Tirzepatide" — and for its combination products.
- It publishes a real price on its weight-loss page: "Monthly Plan Starting At $99 a month", with the shipping interval stated as every four weeks.
- It states the shipping cadence explicitly ("shipped every 4 weeks"), which is the fact needed to work out the true annual cost.
Show 6 more
- A staffed telephone line is published with hours — 1-888-397-6905, Monday to Saturday, 8am–8pm ET — which several companies in this roster do not offer.
- It maintains a full set of legal documents: privacy policy, terms and conditions, telehealth consent, and a refund and cancellation policy.
- It sells the approved products alongside compounded ones, so a patient can choose a manufactured drug with an NDC.
- Its core compounded GLP-1 claims are modest — appetite regulation and weight management, with no percentage quoted and no trial name-dropped.
- "Cancel or change anytime" is stated on the monthly plan.
- No FDA warning letter — screened against the live index with a positive control that fired.
- "Energy & Focus+" is a GLP-1 co-formulated with NAD+ and B12, sold for "enhanced cognitive and physical output". No trial has tested that combination, and no trial of either component reports a cognitive endpoint.
- "Muscle & Energy+" stacks four unstudied choices on one molecule — a microdose, an oral route, a four-ingredient combination, and an indication that is explicitly not weight loss.
- Its core compounded products never name the molecule. "Compounded GLP-1/GIP" is tirzepatide, discoverable only from the URL slug `injectable-tirzepatide`.
Show 10 more
- Two lifetime offers that cannot both be true sit on the same page: "Lock In $200 OFF Every Month… For Life" and "New Customer Offer: $150 off for Life".
- "Shipped every 4 weeks" means about 13 charges a year, so "$99 a month" is roughly $1,287 a year rather than $1,188.
- Ozempic at $1,399 and Zepbound at $1,599 a month are far above the manufacturers' direct self-pay prices for the same products.
- Asked "What states do you serve?", its own FAQ answers "eligibility is checked during sign-up" — a process, not a coverage list.
- "FDA-regulated pharmacies" misdescribes oversight: 503A pharmacies are licensed and inspected by state boards.
- No pharmacy is named, no compounding category is stated, and no certificate of analysis or test result is published.
- Nothing addresses compatibility, stability or per-component potency for its multi-ingredient sterile injections.
- "Most members begin seeing results within the first few weeks" is a timeline claim with no source.
- Most product pages render no price at all — the Shopify variants return $0.00 and the figure appears only after the eligibility quiz.
- The footer copyright is 2025 on product pages and 2026 on the landing page.
Verdict
The bottom line
WellMedr's core business is an ordinary compounded GLP-1 operation with modest claims, a published $99 starting price and a phone number you can actually ring. What makes it worth a review on this site is the product beside it. "Energy & Focus+" is compounded tirzepatide mixed into one injection with NAD+ and vitamin B12 and sold for "enhanced cognitive and physical output" — a combination no registered trial has tested, in which one component has a large phase 3 programme that never measured cognition and another has no completed human trial at all. "Muscle & Energy+" goes further, stacking a microdose, an oral route, four ingredients and an explicitly non-weight-loss indication onto the same molecule. Nothing on the site addresses whether a multi-ingredient sterile injection is stable or potent in each part, no pharmacy is named, and no certificate exists. Alongside that: the core compounded products never name the molecule outside their URL, two incompatible lifetime discounts run on one page, and the four-week shipping cycle quietly turns "$99 a month" into thirteen charges a year.
Opens www.wellmedr.com. A link is not a recommendation to take anything.
A GLP-1 in the same syringe as NAD+
Most companies in this review series sell GLP-1s, and several sell NAD+. WellMedr is the first to sell them in the same injection.
Its product "Energy & Focus+", verbatim:
"Compounded Tirzepatide injection formulated with NAD+ and Vitamin B12 to help support balanced focus, sustained energy, and metabolic performance. Designed for individuals seeking enhanced cognitive and physical output through GLP-1/GIP–based therapy."
There is a second version built the same way on semaglutide. And a third, "Muscle & Energy+":
"Compounded oral microdose GLP-1/GIP* (contains Tirzepatide), formulated with NAD+, L-Carnitine, and Vitamin B12… without a primary weight-loss emphasis."
Take those apart against the evidence.
Tirzepatide has a large, genuine phase 3 programme. Every trial in it measured weight, glycaemia or cardiovascular outcomes. 2 None measured focus, cognition or "cognitive output".
Injected NAD+ has no completed randomised human trial supporting a restoration-of-function claim, and no registered study reports a cognitive endpoint for NAD+ by any route. 1
The combination has never been tested. A ClinicalTrials.gov search returns no registered trial of tirzepatide co-formulated or co-administered with NAD+, in any phase, for any endpoint — while the same search returns 158 records for tirzepatide on its own, so the instrument works.
So a product whose selling proposition is cognition contains one ingredient never trialled for cognition, one ingredient never trialled at all, and a pairing nobody has studied. The word "formulated" does quiet work here: it implies deliberate pharmacological design, and what is published supports none.
B12 is the one component with a real cognitive story, and it is narrow — correcting a B12 deficiency can improve cognition. That is not a reason to give B12 to someone who is not deficient, and the page never raises the distinction.
"Muscle & Energy+" is the furthest out. It stacks four unstudied choices on one molecule: a deliberately sub-therapeutic dose, an oral route for a compounded tirzepatide, a four-ingredient combination, and an indication that is explicitly not the one tirzepatide has been trialled for.
Full analysis — 5 more sectionsThe molecule is in the URL · Two lifetime offers on one page · What $99 a month actually costs · Who makes it, and where you can get it · What this means if you are buying
The molecule is in the URL
WellMedr's core compounded products are called:
- "Compounded GLP-1" — handle `injectable-semaglutide`
- "Compounded GLP-1/GIP" — handle `injectable-tirzepatide`
- "Compounded Oral GLP-1" — handle `oral-semaglutide`
- "Compounded Oral GLP-1/GIP" — handle `oral-tirzepatide`
The titles name a receptor class. The descriptions never name the molecule either. The only place a buyer can learn what they are being prescribed is the URL slug.
What makes this a choice rather than an oversight is that WellMedr names the molecule everywhere else. Ozempic's description says "Contains Semaglutide". Zepbound's says "Contains Tirzepatide". Both "Energy & Focus+" products name theirs, and "Muscle & Energy+" says "(contains Tirzepatide)".
Only the core compounded line is anonymous.
Two lifetime offers on one page
At the top of WellMedr's weight-loss page:
"🎉 Lock In $200 OFF Every Month, or $59/mo on 12/month Plans — For Life."
Further down the same page:
"New Customer Offer: $150 off for Life. Welcome to Wellmedr. Join today and lock in $150 off for life — no long term commitments."
$200 off for life and $150 off for life cannot both be the offer. Neither carries a date or a condition that reconciles them.
What $99 a month actually costs
The published price is real and easy to find, which is more than several competitors manage:
"⭐ Recommended for most patients — Monthly Plan Starting At $99 a month — Shipped every 4 weeks — ✔ Tirzepatide shipped every 4 weeks ✔ Dosing adjusted as your body responds ✔ Cancel or change anytime"
The important words are "shipped every 4 weeks". A 52-week year holds 13 four-week cycles, not 12. So "$99 a month" is about $1,287 a year, not $1,188.
WellMedr states the cadence plainly, which is to its credit — the arithmetic is left to the reader, but the fact needed to do it is on the page.
The branded products are a different matter: Ozempic at $1,399 a month and Zepbound at $1,599. Novo Nordisk and Eli Lilly both sell those exact products to self-paying patients through their own direct channels for a fraction of that, and any telehealth prescriber can send a prescription there.
(One accuracy note WellMedr does not make: Ozempic is approved for type 2 diabetes. Wegovy is the weight-management approval of the same molecule. Selling Ozempic on a weight-loss page is off-label — lawful and routine, but not the approved indication.)
Who makes it, and where you can get it
Neither is answered.
No dispensing pharmacy is named. The site offers two phrases instead: "accredited pharmacies", which names no accrediting body, and a banner reading "FDA-regulated pharmacies", which misdescribes how compounding is overseen — a 503A pharmacy is licensed and inspected by its state board, not regulated by FDA. WellMedr states no compounding category at all.
That gap matters more here than usual. WellMedr's distinctive products are multi-ingredient sterile injections, and mixing tirzepatide with NAD+ and B12 raises questions a single-molecule preparation does not: compatibility, stability, and whether each component is still at its stated potency by the end of a vial. Nothing on the site addresses any of it, and no certificate of analysis, lot number or test result is published for anything.
On coverage, WellMedr's own FAQ asks the question and declines it:
"What states do you serve? We are expanding rapidly — eligibility is checked during sign-up."
That is a description of a process, not an answer. A prospective patient cannot find out whether they are eligible without starting an intake.
To its credit, WellMedr publishes a real telephone line with hours — 1-888-397-6905, Monday to Saturday, 8am–8pm ET — plus privacy, terms, telehealth-consent and refund documents, which is a fuller set than several companies here maintain.
What this means if you are buying
For a plain compounded GLP-1, WellMedr is unremarkable in the good sense: modest claims, a published starting price, a phone number. Check the URL to confirm which molecule you are getting, and budget thirteen charges a year rather than twelve.
Do not buy Ozempic or Zepbound here at $1,399 and $1,599 without first checking the manufacturers' own direct-to-patient prices.
And treat "Energy & Focus+" and "Muscle & Energy+" as what they are: combinations assembled for a purpose neither active ingredient has been trialled for. If you want a GLP-1, the evidence for that is strong and it does not require NAD+ in the syringe. If you want the cognitive benefit the name promises, there is no trial behind it — and a multi-ingredient sterile injection with no published stability or potency data is the least verifiable way to pursue it.
Questions
Frequently asked questions
Is there evidence for mixing a GLP-1 with NAD+?
None. As of 10 August 2026, a ClinicalTrials.gov search returns no registered trial of tirzepatide or semaglutide co-formulated or co-administered with NAD+, in any phase, for any endpoint — while the same search returns 158 records for tirzepatide alone, so the instrument discriminates. Each component fails separately too: tirzepatide's phase 3 programme measured weight, glycaemia and cardiovascular outcomes and never cognition, and injected NAD+ has no completed randomised human trial at all and none reporting a cognitive endpoint by any route. WellMedr's "Energy & Focus+" is sold for "enhanced cognitive and physical output", which is an intention rather than a demonstrated effect. Vitamin B12, the third ingredient, has a real but narrow cognitive story — correcting a deficiency can help — which is not a reason to give it to someone who is not deficient.
Which drug is WellMedr's "Compounded GLP-1/GIP"?
Tirzepatide — and you can only learn that from the URL. WellMedr's core compounded products are titled by receptor class ("Compounded GLP-1", "Compounded GLP-1/GIP", and oral versions of each), and their descriptions never name the molecule. The product handles do: injectable-semaglutide, injectable-tirzepatide, oral-semaglutide, oral-tirzepatide. What makes this a choice rather than an oversight is that WellMedr names the molecule everywhere else on the site — Ozempic "Contains Semaglutide", Zepbound "Contains Tirzepatide", and both combination products name theirs. Only the core compounded line is anonymous. Check the address bar before you buy.
What does WellMedr actually cost per year?
More than the monthly figure suggests, because of the shipping cadence. Its weight-loss page advertises a "Monthly Plan Starting At $99 a month" and states plainly that it is "shipped every 4 weeks". A 52-week year contains 13 four-week cycles rather than 12, so $99 a month is roughly $1,287 a year rather than $1,188. WellMedr deserves credit for stating the cadence — the arithmetic is left to you, but the fact you need is on the page. Two other things to watch: the branded products are priced far above the manufacturers' own direct self-pay channels, at $1,399 a month for Ozempic and $1,599 for Zepbound; and two incompatible lifetime discounts appear on the same page, "$200 OFF Every Month… For Life" at the top and "$150 off for Life" further down.
Does WellMedr say which pharmacy makes its medication?
No, and its two quality phrases do not survive checking. "Accredited pharmacies" names no accrediting body, and the site-wide banner "FDA-regulated pharmacies" misdescribes the oversight: a 503A compounding pharmacy is licensed and inspected by its state board, not regulated by FDA. WellMedr states no compounding category anywhere, names no pharmacy, and publishes no certificate of analysis, lot number, potency or sterility result. That gap is more consequential here than at most companies in this roster, because WellMedr's distinctive products are multi-ingredient sterile injections — tirzepatide with NAD+ and B12 in one syringe — which raise compatibility, stability and per-component potency questions that a single-molecule preparation does not. Nothing on the site addresses them.
Does WellMedr serve my state?
It will not say. Its own FAQ asks the question and answers with a process: "What states do you serve? We are expanding rapidly — eligibility is checked during sign-up." No state list, map or exclusion notice appears anywhere on the site, so a prospective patient cannot establish eligibility without starting an intake. No medical group is named and no individual clinician or licence number is published; clinical oversight appears only as "licensed U.S. providers". WellMedr does publish a staffed telephone line with hours — 1-888-397-6905, Monday to Saturday, 8am to 8pm ET — which is the one route available for asking before you commit.
Glossary
Key terms
Show definitions
- Co-formulation
- Combining two or more active ingredients in a single preparation. It raises questions a single-ingredient product does not — chemical compatibility, stability over the vial's life, and whether each component holds its stated potency — none of which WellMedr addresses.
- "FDA-regulated pharmacy"
- A misdescription. 503A compounding pharmacies are licensed and inspected by state boards of pharmacy. 503B outsourcing facilities register with FDA and are subject to inspection, but registration is not the blanket regulation the phrase implies.
- Four-week cycle
- A 28-day shipping and billing interval. A 52-week year holds 13 of them, not 12, so a "monthly" price billed this way costs about 8% more per year than it appears to.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off WellMedr's own pages on the date stamped against it, and the URL it came from is published beside it.
Trials read from the registry
Phase, status and enrolment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 3 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected NAD+ in humans, and for tirzepatide or semaglutide combined with NAD+: no completed randomised trial supporting a restoration-of-function claim, no registered study reporting a cognitive endpoint for NAD+ by any route, and no registered trial of a GLP-1 co-formulated or co-administered with NAD+ in any phase. Positive control in the same pass: tirzepatide alone returns 158 records naming it as an intervention. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.